Law360 (March 27, 2008, 12:00 AM EDT) -- The U.S. subsidiary of Japanese pharmaceutical company Otsuka Pharmaceutical Co. Ltd. has agreed to pay $4 million to settle off-label marketing allegations brought by the U.S. Department of Justice.
The DOJ said Thursday that Otsuka American Pharmaceutical Inc. had agreed to the settlement, putting to rest claims that the company marketed its anti-psychotic drug Abilify for off-label uses by targeting child psychiatrists and nursing homes.
The settlement comes six months after Bristol-Myers Squibb Co. entered into an agreement with the government concerning similar allegations regarding its promotion of Abilify.
Otsuka and BMS had entered into an agreement to co-promote the drug...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!